Glaukos reports Q3 adjusted EPS (28c), consensus (48c)

Reports Q3 revenue $96.7M, consensus $91.49M. “Our record third quarter results reflect successful global execution of our key strategic plans and continued strong momentum in our business,” said Thomas Burns, Glaukos (GKOS) chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”